Vaxxinity
Edit info- Founded: 2014
- Location: Dallas, TX
- Employee range: 50 - 200
- Clinical stage: Clin3
- Therapy area: COVID-19
- Drug types: NEU, VAC, INF, CVV
- Lead product: UB-612
- Funding: $85M IPO Nov 2021
vaxxinity.com linkedin.com job board
Business:
Endobody Vaccines, Synthetic Peptides Vaccine
Drug notes:
UB-311 Clin2 Alzheimer's; UB-312 Clin1 Parkinson's, DLB, MSA; UB-313 Clin1 migraine; VXX-401 Clin1 hypercholesterolemia; undisclosed RD/Clin0 Alzheimer's, undisclosed
About:
Vaxxinity is a pioneering biotechnology company dedicated to advancing vaccine development through innovative scientific approaches. Leveraging state-of-the-art molecular biology and immunology techniques, Vaxxinity focuses on designing next-generation vaccines that target chronic diseases, which are currently expensive treatments with less than 1% of the global population. Their scientific endeavors emphasize the use of novel antigen design, adjuvant technologies, and vaccine delivery systems to enhance efficacy, safety, and scalability. With a commitment to rigorous research and clinical validation, Vaxxinity aims to contribute significantly to public health by addressing current and emerging infectious and chronic threats with affordable treatments.
Jobs:
News:
Vaxxinity's Cholesterol Vaccine Candidate Successfully
crunchbase
Mar 5, 2024
Science/business updates
external-link
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with ...
crunchbase
Jan 30, 2024
Science/business updates
external-link
Study: Therapeutic Parkinson's vaccine safely inhibits alpha-synuclein clumps - Parkinson's News Today
googlenews
Jun 27, 2024
Science/business updates
external-link
Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space
crunchbase
Feb 1, 2024
Science/business updates
external-link
Researchers return to Alzheimer's vaccines, buoyed by recent ...
crunchbase
Nov 24, 2023
Science/business updates
external-link
Vaxxinity Alzheimer’s treatment shows promising results in early trial - BioPharma-Reporter.com
googlenews
Aug 15, 2023
Science/business updates
external-link
Private companies in Vaxxinity, Inc. (NASDAQ:VAXX) are its biggest bettors, and their bets paid off as stock gained 22% last week
crunchbase
Mar 1, 2024
Funding-related
external-link
Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia ...
crunchbase
Sep 29, 2023
Science/business updates
external-link
Vaxxinity Appoints Dr. Peter Powchik as Global Scientific ...
crunchbase
Jul 28, 2023
New hires
external-link
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
crunchbase
Nov 13, 2023
Science/business updates
external-link
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease - South Florida Hospital News
googlenews
Jun 26, 2023
Science/business updates
external-link
Vaccine trial for early Parkinson’s meets primary objectives |... - Parkinson's News Today
googlenews
Jun 26, 2023
Science/business updates
external-link
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
googlenews
Oct 10, 2023
Funding-related
external-link
Biotech Companies Launch or Plan IPOs: Vaxxinity, Genenta and Enetrada - BioSpace
googlenews
Nov 11, 2021
Funding-related
external-link
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
googlenews
Mar 11, 2024
Science/business updates
external-link
Method for the prevention and treatment of coronavirus disease
crunchbase
Oct 18, 2022
Science/business updates
external-link
Could space travel research deliver a frailty vaccine? - Longevity.Technology
googlenews
Jan 18, 2024
Science/business updates
external-link
Vaxxinity celebrates trial success in early Parkinson’s therapy - Clinical Trials Arena
googlenews
Jun 23, 2023
Science/business updates
external-link
Vaxxinity Announces Positive Target Engagement Data from - GlobeNewswire
googlenews
Mar 7, 2024
Science/business updates
external-link
Why Vaxxinity (VAXX) Shares Are Down Nearly 50% - Vaxxinity (OTC:VAXX)
crunchbase
Apr 26, 2024
Science/business updates
external-link
Peek inside the Space Coast vaccine lab working to create humanity’s moonshot - WFTV Orlando
googlenews
Feb 22, 2024
Science/business updates
external-link
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
crunchbase
Feb 1, 2024
Science/business updates
external-link
Vaxxinity seeks a partner to press ahead with Alzheimer's ...
fiercebiotech.com
Dec 27, 2024
Science/business updates
external-link
Vaxxinity will push for approval of COVID booster after trial shows noninferiority to market leader Pfizer - Fierce Biotech
googlenews
Dec 2, 2022
Science/business updates
external-link
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
crunchbase
Jul 27, 2023
New hires
external-link
Vaxxinity Has a Rough Public Debut - The Motley Fool
googlenews
Nov 28, 2021
Science/business updates
external-link
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace
googlenews
Apr 22, 2024
Science/business updates
external-link
Migraine Vaccine Shows Comparable Efficacy to Monoclonal Antibodies for Migraine Relief: Jean-Cosme Dodart, PhD - Neurology Live
googlenews
May 10, 2023
Science/business updates
external-link
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD ...
crunchbase
Mar 7, 2024
Science/business updates
external-link
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine - GlobeNewswire
googlenews
Jun 20, 2024
Science/business updates
external-link
Parkinson’s vaccine targets toxic alpha-synuclein in Phase 1 trial - Parkinson's News Today
googlenews
Jul 19, 2023
Science/business updates
external-link
Positive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s Disease - Yahoo Finance
googlenews
Jun 22, 2023
Science/business updates
external-link
Vaxxinity moves HQ, jobs to Florida's Space Coast from Texas
crunchbase
Feb 9, 2023
New hires
external-link
Vaxxinity making vaccines to change the world - Labiotech.eu
googlenews
Dec 15, 2023
Science/business updates
external-link
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - Yahoo Finance
googlenews
Apr 19, 2024
Science/business updates
external-link
Sars-cov-2 vaccine for the prevention and treatment of coronavirus disease ( …
crunchbase
Feb 9, 2023
Science/business updates
external-link
Vaxxinity Plans to Delist Shares From Nasdaq
crunchbase
Apr 17, 2024
Science/business updates
external-link
Parkinson’s vaccine seen to target toxic alpha-synuclein in Phase 1 trial - Parkinson's News Today
googlenews
Mar 11, 2024
Science/business updates
external-link
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology
googlenews
Mar 8, 2024
Science/business updates
external-link
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
googlenews
May 3, 2024
Science/business updates
external-link
MULTIEPITOPIC PROTEIN/PEPTIDE BASED VACCINE AGAINST SARS-CoV-2 FOR THE …
crunchbase
Aug 12, 2022
Science/business updates
external-link
Vaxxinity, hoping to turn bodies into their own drug ...
fiercebiotech.com
Dec 27, 2024
Science/business updates
external-link
Researchers return to Alzheimer's vaccines, buoyed by recent drug success - Reuters.com
googlenews
Nov 20, 2023
Science/business updates
external-link
Vaxxinity Announces Publication of UB-311 Safety ...
crunchbase
Aug 10, 2023
Science/business updates
external-link
CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants - CEPI
googlenews
Apr 5, 2022
Funding-related
external-link
Dallas-Based Vaxxinity Prepares for $100M IPO; Aims to Turn Immune Systems Into 'Antibody Factories' - dallasinnovates.com
googlenews
Nov 8, 2021
Funding-related
external-link
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX) - Yahoo Finance
googlenews
Sep 7, 2023
Science/business updates
external-link
Why Vaxxinity (VAXX) Shares Are Volatile Today - Vaxxinity (OTC:VAXX)
crunchbase
Apr 26, 2024
Science/business updates
external-link
Vaxxinity vaccine to treat Alzheimer’s wins FDA fast track designation - The Dallas Morning News
googlenews
May 2, 2022
Science/business updates
external-link
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
googlenews
Jun 21, 2024
Science/business updates
external-link
A Potential Parkinson’s Treatment Has Promising Results - TIME
googlenews
Jun 20, 2024
Science/business updates
external-link
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
googlenews
Mar 28, 2024
Science/business updates
external-link
Robert W. Baird analysts initates an Outperform rating for Vaxxinity Inc (VAXX) – Knox Daily
crunchbase
Feb 28, 2024
Funding-related
external-link
Sars-cov-2 multitope peptide/protein vaccine for the prevention and treatment …
crunchbase
Aug 12, 2022
Science/business updates
external-link
How Is The Market Feeling About Vaxxinity?
crunchbase
May 2, 2022
Science/business updates
external-link
Fast-Tracked Alzheimer’s Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient
googlenews
Aug 28, 2023
Science/business updates
external-link
CEPI to co-fund Vaxxinity's Phase III UB-612 trial to combat SARS-CoV-2 variants - The Pharma Letter
googlenews
Apr 7, 2022
Funding-related
external-link
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
googlenews
Aug 27, 2024
Science/business updates
external-link
Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study - Yahoo Finance
googlenews
Jan 13, 2022
Science/business updates
external-link
Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity
crunchbase
Aug 12, 2022
Science/business updates
external-link
Gov. DeSantis appoints former Donald Trump adviser, biotech chief to PBSC Board of Trustees - Florida Politics
googlenews
Mar 20, 2024
New hires
external-link
Vaxxinity Signs Purchase Order with the Government of Paraguay for 1 Million Doses of Vaxxinity’s UB-612 COVID-19 Vaccine - Business Wire
googlenews
Jun 21, 2021
Science/business updates
external-link
Could space travel research deliver a frailty vaccine?
crunchbase
Jan 21, 2024
Science/business updates
external-link
Fast-Tracked Alzheimer's Vaccine Seems to Work, But Phase 3 Trials Stalled
crunchbase
Aug 28, 2023
Science/business updates
external-link
Parkinson’s vaccine, UB-312, slows alpha-synuclein clumping in patients - Parkinson's News Today
googlenews
Nov 13, 2023
Science/business updates
external-link
Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer's treatment - Fierce Biotech
googlenews
Mar 27, 2023
Funding-related
external-link
Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida
crunchbase
Feb 1, 2023
New hires
external-link
Vaxxinity to voluntarily delist, deregister its Class A common stock
crunchbase
Apr 19, 2024
Science/business updates
external-link
Experimental Parkinson’s Treatment Elicits Antibodies Against Toxic Protein in Phase I - BioSpace
googlenews
Jun 20, 2024
Science/business updates
external-link
New Wave of Alzheimer’s Therapies Actively Engage the Immune System - BioSpace
googlenews
Aug 5, 2024
Science/business updates
external-link
Vaxxinity Wants to Bring Accessible Vaccines for Chronic Illness to Market
linkedin
Jan 27, 2024
Science/business updates
external-link
Vaccines show promise against common chronic diseases - Gavi, the Vaccine Alliance
googlenews
Jan 15, 2024
Science/business updates
external-link
Vaxxinity to Present at Upcoming Investor Conferences in September
crunchbase
Aug 29, 2023
Funding-related
external-link
Vaxxinity will push for approval of COVID booster after trial shows noninferiority to market leader Pfizer
crunchbase
Dec 2, 2022
Science/business updates
external-link
Vaxxinity (VAXX) Stock Price, News & Analysis - MarketBeat
googlenews
Nov 27, 2021
Science/business updates
external-link
Vaxxinity hopes its Covid jab technology will help treat Alzheimer’s - Financial Times
googlenews
Jun 12, 2021
Science/business updates
external-link
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
crunchbase
Jun 30, 2024
Science/business updates
external-link
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewswire
googlenews
Mar 27, 2024
Science/business updates
external-link
COVAXX and United Neuroscience Are Now Vaxxinity - Business Wire
googlenews
Apr 1, 2021
Science/business updates
external-link
Vaxxinity Issues Shareholder Letter - GlobeNewswire
googlenews
Apr 19, 2024
Funding-related
external-link
Vaxxinity Announces First Subjects Dosed in Phase 1 - GlobeNewswire
googlenews
Mar 20, 2023
Science/business updates
external-link
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
googlenews
May 15, 2024
Science/business updates
external-link
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market
crunchbase
May 15, 2024
Science/business updates
external-link
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap ...
crunchbase
Oct 10, 2023
Funding-related
external-link
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com